Therapeutic Plasma Exchange in the Treatment of Sepsis Associated Multi-Organ Failure [SAMOF-TPE]

Overview

The investigators prospective, randomized adult clinical trial investigates the therapeutic efficacy of early therapeutic plasma exchange as adjunct treatment to standard therapy in patients with refractory septic shock and multiple organ failure.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2022

Interventions

  • Device: Therapeutic plasma exchange
    • Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure

Arms, Groups and Cohorts

  • Experimental: Therapeutic plasma exchange
    • Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
  • No Intervention: Standard care alone for sepsis
    • Standard care for patients with sepsis induced multi-organ failure

Clinical Trial Outcome Measures

Primary Measures

  • 28-Day Mortality
    • Time Frame: 28 days
    • 28 days

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients are eligible for inclusion if they have sepsis with refractory shock and evidence of organ failure. Exclusion Criteria:

  • Persons who are pregnant – Persons who are incarcerated – Acute surgical catastrophe without potential for intervention or source control – Cardiac arrest with unknown neurologic status, including patients being treated with therapeutic hypothermia – Presence of severe acute brain injury or severe dementia – Cardiogenic, neurogenic, obstructive, or post-cardiotomy shock – Acute pancreatitis with no established source of infection – Diabetic ketoacidosis as primary pathology – Note: Septic patients who develop DKA are eligible for inclusion. However, patients in whom organ dysfunction and hemodynamic instability are due primarily to volume depletion and acidosis from DKA should not be included. – Need for mechanical circulatory support – Prolonged acute illness with > 24 hours of pressor needs at enrollment and/or end organ damage with further care deemed to be "futile." – NOTE: The time resets if a new inciting event leads to SAMOF. – For example, if a patient has sepsis stabilized but requires operative intervention for source control within the initial 24 hours of admission and returns to the ICU with SAMOF, the patient is again eligible for randomization for the next 24 hours. – Bedbound state or poor baseline functional status with ECOG performance status score ≥ 3 – Underlying terminal illness/malignancy with < 6 months life expectancy – Advanced chronic liver disease/cirrhosis with evidence of portal hypertension – Asplenia – HIV with HARRT non-compliance

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Forsyth Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Philip Keith, MD, 843.693.0412, pkeith@salemchest.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.